Prospective Grant of Exclusive Patent Commercialization License: Direct Reading Detection Kits for Surface Contamination by Antineoplastic Drugs, 53512-53513 [2017-24774]
Download as PDF
<![CDATA[
asabaliauskas on DSKBBXCHB2PROD with NOTICES
53512
Federal Register / Vol. 82, No. 220 / Thursday, November 16, 2017 / Notices
433: Support of NIGMS Program Project
Grants.
Date: November 29, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Eduardo A. Montalvo,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
MSC 7852, Bethesda, MD 20892, (301) 435–
1168, montalve@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: AIDS and Related Research.
Date: December 1, 2017.
Time: 3:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Robert Freund, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5216,
MSC 7852, Bethesda, MD 20892, 301–435–
1050, freundr@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
AIDS and AIDS-Related Research.
Date: December 7, 2017.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Robert Freund, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5216,
MSC 7852, Bethesda, MD 20892, 301–435–
1050, freundr@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Developmental Abnormalities of the
Nervous System.
Date: December 8, 2017.
Time: 2:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Suzan Nadi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5217B,
MSC 7846, Bethesda, MD 20892, 301–435–
1259, nadis@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR17–031:
Role of Age-Associated Metabolic Changes in
Alzheimer’s Disease.
Date: December 13, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
VerDate Sep<11>2014
16:52 Nov 15, 2017
Jkt 244001
Contact Person: Alessandra C Rovescalli,
Ph.D., Scientific Review Officer, National
Institutes of Health, Center for Scientific
Review, 6701 Rockledge Drive, Rm. 5205,
MSC 7846, Bethesda, MD 20892, (301) 435–
1021, rovescaa@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 9, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–24759 Filed 11–15–17; 8:45 am]
BILLING CODE 4140–01–P
Dated: November 9, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–24761 Filed 11–15–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
Commercialization License: Direct
Reading Detection Kits for Surface
Contamination by Antineoplastic
Drugs
Centers for Disease Control and
Prevention, National Institutes of
Health.
ACTION: Notice.
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Division of Intramural
Research Board of Scientific Counselors,
NIAID. The meeting will be closed to
the public as indicated below in
accordance with the provisions set forth
in section 552b(c)(6), Title 5 U.S.C., as
amended for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Institute of Allergy and
Infectious Diseases, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Division of Intramural
Research Board of Scientific Counselors,
NIAID.
Date: December 11–13, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 50, 1227/1233, 50 Center Drive,
Bethesda, MD 20892.
Contact Person: Steven M. Holland, MD,
Ph.D., Chief, Laboratory of Clinical Infectious
Diseases, National Institutes of Health/
NIAID, Hatfield Clinical Research Center,
Bethesda, MD 20892–1684, 301–402–7684,
sholland@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, on behalf of the
Centers for Disease Control and
Prevention, Department of Health and
Human Services, is contemplating the
grant of an exclusive patent
commercialization license to Becton,
Dickinson and Company, located in
Franklin Lakes, New Jersey, to practice
the inventions embodied in the patent
applications listed in the
Supplementary Information section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the Technology Transfer
and Intellectual Property Office,
National Institute of Allergy and
Infectious Diseases on or before
December 1, 2017 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent commercialization
license should be directed to: Karen
Surabian, Licensing and Patenting
Manager, Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Suite 2G,
MSC9804, Rockville, MD 20852–9804,
phone number 301–594–9719, or
karen.surabian@nih.gov.
SUPPLEMENTARY INFORMATION: The
following represents the intellectual
property to be licensed under the
prospective agreement: HHS Reference
No. E–162–2013/0–US–01, United
States Provisional Patent Application
Serial Number 61/672,059, filed 07/16/
2012; HHS Reference No. E–162–2013/
0–PCT–02, PCT Patent Application
SUMMARY:
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
E:\FR\FM\16NON1.SGM
16NON1
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 220 / Thursday, November 16, 2017 / Notices
Serial Number PCT/US2013/050688,
filed 07/16/2013; HHS Reference No. E–
162–2013/0–US–03, United States
Patent Application Serial Number 13/
943,430, filed 07/16/2013; HHS
Reference No. E–162–2013/0–EP–04,
European Patent Application Serial
Number 13819718.1, filed 02/05/2015;
and HHS Reference No. E–162–2013/0–
JP–05, Japanese Patent Application
Serial Number 2015–523183, filed 01/
08/2015. All rights in these inventions
have been assigned to the Government
of the United States of America.
The prospective exclusive patent
commercialization license territory may
be worldwide and the field of use may
be limited to: ‘‘Use of the licensed
patent rights for the development,
manufacture, and sale of a lateral flow
device for detection of antineoplastic
drugs from surfaces’’.
Many types of cancers are treated
with antineoplastic drugs, also known
as anti-cancer drugs or chemotherapy.
Exposure of healthcare workers to these
hazardous drugs from contaminated
surfaces may cause acute and long-term
effects. Approximately eight (8) million
United States healthcare workers are
potentially exposed to these hazardous
drugs. Although there are potential
therapeutic benefits of hazardous drugs
that outweigh the risks of side effects for
ill patients, healthcare workers are
exposed to the risk with the same side
effects with no therapeutic benefit.
Occupational exposures to hazardous
drugs can lead to skin rashes and major
reproductive effects, which include
increased fetal loss, congenital
malformations, low birth weight,
congenital abnormalities, and infertility.
The risk of cancer is also increased after
exposure to these drugs.
This invention, developed within the
National Institute for Occupational
Safety and Health at the Centers for
Disease Control and Prevention,
describes a lateral flow assay-based
antineoplastic drug detection method
that utilizes antibodies specific for
individual drugs. It uses detectors for
the assessment of drug residues on
surfaces, which can be incorporated into
small, portable drug detection devices
that allow healthcare workers to sample
surfaces in near real time, avoiding the
need to take samples back to the
laboratory to be tested.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent
commercialization license will be
royalty bearing and may be granted
unless within fifteen (15) days from the
date of this published notice, the
National Institute of Allergy and
Infectious Diseases receives written
VerDate Sep<11>2014
16:52 Nov 15, 2017
Jkt 244001
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive patent
commercialization license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: November 9, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–24774 Filed 11–15–17; 8:45 am]
BILLING CODE 4140–01–P
53513
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: November 9, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–24760 Filed 11–15–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Internal Agency Docket No. FEMA–4344–
DR; Docket ID FEMA–2017–0001]
California; Amendment No. 5 to Notice
of a Major Disaster Declaration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
National Institutes of Health
SUMMARY:
AGENCY:
National Eye Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, National Eye Institute.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual grant
applications conducted by the
NATIONAL EYE INSTITUTE, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, National Eye Institute.
Date: December 3–5, 2017.
Time: 6:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Conference Room 6C6, 31
Center Drive, Bethesda, MD 20892.
Contact Person: Sheldon S. Miller, Ph.D.,
Scientific Director, National Institutes of
Health, National Eye Institute, Bethesda, MD
20892, (301) 451–6763.
Information is also available on the
Institute’s/Center’s home page:
www.nei.nih.gov, where an agenda and any
additional information for the meeting will
be posted when available.
PO 00000
Frm 00064
Fmt 4703
Sfmt 9990
This notice amends the notice
of a major disaster declaration for the
State of California (FEMA–4344–DR),
dated October 10, 2017, and related
determinations.
This amendment was issued
November 7, 2017.
FOR FURTHER INFORMATION CONTACT:
Dean Webster, Office of Response and
Recovery, Federal Emergency
Management Agency, 500 C Street SW.,
Washington, DC 20472, (202) 646–2833.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the incident period for
this disaster is closed effective October
31, 2017.
DATES:
The following Catalog of Federal Domestic
Assistance Numbers (CFDA) are to be used
for reporting and drawing funds: 97.030,
Community Disaster Loans; 97.031, Cora
Brown Fund; 97.032, Crisis Counseling;
97.033, Disaster Legal Services; 97.034,
Disaster Unemployment Assistance (DUA);
97.046, Fire Management Assistance Grant;
97.048, Disaster Housing Assistance to
Individuals and Households In Presidentially
Declared Disaster Areas; 97.049,
Presidentially Declared Disaster Assistance—
Disaster Housing Operations for Individuals
and Households; 97.050 Presidentially
Declared Disaster Assistance to Individuals
and Households—Other Needs; 97.036,
Disaster Grants—Public Assistance
(Presidentially Declared Disasters); 97.039,
Hazard Mitigation Grant.
Brock Long,
Administrator, Federal Emergency
Management Agency.
[FR Doc. 2017–24910 Filed 11–15–17; 8:45 am]
BILLING CODE 9111–23–P
E:\FR\FM\16NON1.SGM
16NON1
]]>Agencies
[Federal Register Volume 82, Number 220 (Thursday, November 16, 2017)]
[Notices]
[Pages 53512-53513]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24774]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent Commercialization License:
Direct Reading Detection Kits for Surface Contamination by
Antineoplastic Drugs
AGENCY: Centers for Disease Control and Prevention, National Institutes
of Health.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases, an
institute of the National Institutes of Health, Department of Health
and Human Services, on behalf of the Centers for Disease Control and
Prevention, Department of Health and Human Services, is contemplating
the grant of an exclusive patent commercialization license to Becton,
Dickinson and Company, located in Franklin Lakes, New Jersey, to
practice the inventions embodied in the patent applications listed in
the Supplementary Information section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases on or
before December 1, 2017 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent
commercialization license should be directed to: Karen Surabian,
Licensing and Patenting Manager, Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Suite 2G, MSC9804, Rockville, MD 20852-9804, phone
number 301-594-9719, or karen.surabian@nih.gov.
SUPPLEMENTARY INFORMATION: The following represents the intellectual
property to be licensed under the prospective agreement: HHS Reference
No. E-162-2013/0-US-01, United States Provisional Patent Application
Serial Number 61/672,059, filed 07/16/2012; HHS Reference No. E-162-
2013/0-PCT-02, PCT Patent Application
[[Page 53513]]
Serial Number PCT/US2013/050688, filed 07/16/2013; HHS Reference No. E-
162-2013/0-US-03, United States Patent Application Serial Number 13/
943,430, filed 07/16/2013; HHS Reference No. E-162-2013/0-EP-04,
European Patent Application Serial Number 13819718.1, filed 02/05/2015;
and HHS Reference No. E-162-2013/0-JP-05, Japanese Patent Application
Serial Number 2015-523183, filed 01/08/2015. All rights in these
inventions have been assigned to the Government of the United States of
America.
The prospective exclusive patent commercialization license
territory may be worldwide and the field of use may be limited to:
``Use of the licensed patent rights for the development, manufacture,
and sale of a lateral flow device for detection of antineoplastic drugs
from surfaces''.
Many types of cancers are treated with antineoplastic drugs, also
known as anti-cancer drugs or chemotherapy. Exposure of healthcare
workers to these hazardous drugs from contaminated surfaces may cause
acute and long-term effects. Approximately eight (8) million United
States healthcare workers are potentially exposed to these hazardous
drugs. Although there are potential therapeutic benefits of hazardous
drugs that outweigh the risks of side effects for ill patients,
healthcare workers are exposed to the risk with the same side effects
with no therapeutic benefit. Occupational exposures to hazardous drugs
can lead to skin rashes and major reproductive effects, which include
increased fetal loss, congenital malformations, low birth weight,
congenital abnormalities, and infertility. The risk of cancer is also
increased after exposure to these drugs.
This invention, developed within the National Institute for
Occupational Safety and Health at the Centers for Disease Control and
Prevention, describes a lateral flow assay-based antineoplastic drug
detection method that utilizes antibodies specific for individual
drugs. It uses detectors for the assessment of drug residues on
surfaces, which can be incorporated into small, portable drug detection
devices that allow healthcare workers to sample surfaces in near real
time, avoiding the need to take samples back to the laboratory to be
tested.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive patent commercialization license
will be royalty bearing and may be granted unless within fifteen (15)
days from the date of this published notice, the National Institute of
Allergy and Infectious Diseases receives written evidence and argument
that establishes that the grant of the license would not be consistent
with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are timely filed in response to this notice will be treated as
objections to the grant of the contemplated exclusive patent
commercialization license. Comments and objections submitted in
response to this notice will not be made available for public
inspection and, to the extent permitted by law, will not be released
under the Freedom of Information Act, 5 U.S.C. 552.
Dated: November 9, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-24774 Filed 11-15-17; 8:45 am]
BILLING CODE 4140-01-P
